Melchior Benoit, Puntambekar Shweta S, Carson Monica J
Division of Biomedical Sciences, University of California, Riverside, CA 92521, United States.
Neurochem Int. 2006 Jul;49(2):145-53. doi: 10.1016/j.neuint.2006.04.002. Epub 2006 Jun 8.
Microglial activation is one of the earliest and most prominent features of nearly all CNS neuropathologies often occurring prior to other indicators of overt neuropathology. Whether microglial activation in seemingly healthy CNS tissue during the early stages of several is a response to early stages of neuronal or glial distress or an early sign of microglial dysfunction causing subsequent neurodegeneration is unknown. Here we characterize and discuss how changes in the CNS microenvironment (neuronal activity/viability, glial activation) lead to specific forms of microglial activation. Specifically, we examine the potential role that TREM-2 expressing microglia may play in regulating the effector function of autoreactive T cell responses. Thus, we suggest that ubiquitous suppression of microglial activation during CNS inflammatory disorders rather than targeted manipulation of microglial activation, may in the end be maladaptive leading to incomplete remission of symptoms.
小胶质细胞激活是几乎所有中枢神经系统神经病理学最早且最显著的特征之一,通常在明显神经病理学的其他指标出现之前就已发生。在多种疾病的早期阶段,看似健康的中枢神经系统组织中的小胶质细胞激活是对神经元或胶质细胞早期应激的反应,还是小胶质细胞功能障碍导致后续神经退行性变的早期迹象,目前尚不清楚。在这里,我们描述并讨论中枢神经系统微环境的变化(神经元活动/活力、胶质细胞激活)如何导致特定形式的小胶质细胞激活。具体而言,我们研究表达触发受体2(TREM-2)的小胶质细胞在调节自身反应性T细胞反应的效应功能中可能发挥的潜在作用。因此,我们认为,在中枢神经系统炎症性疾病期间普遍抑制小胶质细胞激活,而不是有针对性地操纵小胶质细胞激活,最终可能会产生不良适应,导致症状无法完全缓解。